Investors Buy Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of some unusual options trading on Friday. Stock traders acquired 21,865 call options on the stock. This is an increase of 95% compared to the average volume of 11,198 call options.

SELLAS Life Sciences Group Stock Performance

NASDAQ:SLS traded up $0.06 during mid-day trading on Friday, reaching $2.40. 2,337,140 shares of the company’s stock were exchanged, compared to its average volume of 2,993,071. SELLAS Life Sciences Group has a one year low of $0.85 and a one year high of $2.48. The business’s fifty day simple moving average is $1.78 and its two-hundred day simple moving average is $1.77. The firm has a market capitalization of $341.15 million, a PE ratio of -8.55 and a beta of 2.51.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. As a group, equities research analysts forecast that SELLAS Life Sciences Group will post -0.57 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

Insider Buying and Selling

In other news, Director Katherine Bach Kalin bought 63,400 shares of SELLAS Life Sciences Group stock in a transaction on Wednesday, November 19th. The shares were bought at an average price of $1.59 per share, with a total value of $100,806.00. Following the acquisition, the director directly owned 104,400 shares in the company, valued at approximately $165,996. This represents a 154.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds have recently modified their holdings of the company. Anson Funds Management LP raised its position in SELLAS Life Sciences Group by 535.7% in the first quarter. Anson Funds Management LP now owns 7,579,095 shares of the company’s stock valued at $8,185,000 after purchasing an additional 6,386,829 shares during the period. Vanguard Group Inc. grew its holdings in SELLAS Life Sciences Group by 2.8% in the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after purchasing an additional 185,106 shares during the last quarter. Marshall Wace LLP grew its stake in SELLAS Life Sciences Group by 23,550.0% in the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after acquiring an additional 2,704,007 shares during the period. Geode Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after buying an additional 1,379,988 shares during the period. Finally, GSA Capital Partners LLP grew its stake in shares of SELLAS Life Sciences Group by 21.7% during the third quarter. GSA Capital Partners LLP now owns 518,995 shares of the company’s stock valued at $836,000 after acquiring an additional 92,411 shares in the last quarter. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.